Crescita Therapeutics (Crescita Therapeutics) ROE % Adjusted to Book Value : -7.95% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Crescita Therapeutics ROE % Adjusted to Book Value?

Crescita Therapeutics's ROE % for the quarter that ended in Dec. 2023 was -3.18%. Crescita Therapeutics's PB Ratio for the quarter that ended in Dec. 2023 was 0.40. Crescita Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -7.95%.

Crescita Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Crescita Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crescita Therapeutics ROE % Adjusted to Book Value Chart

Crescita Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

9.63

0.26

-8.05

6.38

-25.03

Crescita Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															36.10	-7.65	-8.63	-37.60	-7.95

Competitive Comparison of Crescita Therapeutics's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Crescita Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crescita Therapeutics's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Crescita Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Crescita Therapeutics's ROE % Adjusted to Book Value falls into.

Crescita Therapeutics ROE % Adjusted to Book Value Calculation

Crescita Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-10.01%	/	0.40
	=	-25.03%

Crescita Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-3.18%	/	0.40
	=	-7.95%

Crescita Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Crescita Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Crescita Therapeutics (Crescita Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Crescita Therapeutics Inc (OTCPK:CRRTF) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

CTX:Canada

Address

2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3

Website

https://www.crescitatherapeutics.com

Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue in the form of product sales and out-licensing revenue.